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Background 
lodinated radiopaque contrast agents are utilized in many 
of the approximately I million or more cardiac carherenza- 
lions performed each year in the United States. Until re- 
cently. the primary agents employed for cardiovascular 
imaging consisted of diatrizoate sodium or a combination of 
diatrizoate sodium and various m&urdne salts. These 
agents are referred to as “ionic” or “idgh osmolar” agent> 
and have osnwlalifies exceeding 1.X0 mOsm!kg. The car- 
diovascular effects of the conventional high osmolar iodi- 
nated contrast agents are well investigated (1-6). 
In recent years (1986 to the present). several “nonionic” 
or “low osmolar” agents have been introduced and wdely 
marketed m the U.S. These include iohexol (Omnipeqx. 
Winthrop). iopamidol (lsovue. Squibb) and ioversol (Opti- 
ray, Mallinckmdtf. An additional agent. ioxaglate (Hex- 
abrix. Mallinckrodt) is best described as an ionic. but low 
osmoiar contrast agent. We will subsequently refer to this 
group of agents interchangeably as either nonionic or low 
osmolar. unless specified otherwise. This policy statement 
does not apply to-other classzs of contrast-agents that may 
become available in the future. All four of these newer 
agents have osmolalities in the range of apprJximarely 6W to 
763 m0smlkg. The cardiovascular e5ects of the newer low 
osmolar agents have been thoroughly investigated during 
premarkeiing surveillance and subsequent clinical use (7- 
14). These data suggest that the low osmolar agents are 
better tolerated than the high osmolar agents and are possi- 
bly safer in hemodynamically compromised patients. hut 
that the low osmolar agents are much more expensive. 
The low osmolar ag&ts cost hospital Qharm&ies approx- 
imately $ltM/lMl ml. This represents approximately IO times 
the cost of conventional ionic agents. Despite the high cost. 
use of these agents is increasing and is now estimated to 
represent approximately 60% to 707~ of currem practice in 
cardiac catheterization. The conversion to the ower low 
osmolar agents for cardiac catheterization represents a sub- 
srantial cost to hospitals. insurers and patients. Total re- 
placement of ionic contrast usage by nonionic agents for 
cardiovascular procedures will add approximately $100 to 
T2W million to the annual U.S. health care budget. Replace- 
ment of ionic agents by nonionic or low osmolar contrast 
media for all radiographic procedures is estimated to add 
$1.1 to I.5 billion to health care costs. Cootroveny exists 
over whether the possible safety benefits of low osmolar 
agents outweigh their substantial increase in costs. 
Intracardiac or intracoronary administration of conven- 
tional high osmolar contrast agents results in major electro- 
p’lysiologic effects. The ionic contt’ast agents reduce the rate 
of depolarization of the sinoa:&d node and prolong the PR 
interval by slowing the attioventricular node conduction. 
These effects produce transient bradycardia in many patients 
and occasionally high grade heart block or sinus arrest. High 
ocmolar agents also produce marked transient alterations in 
T wave configuration of unknown significance. 
The constellation of electrophysiologic effects occurring 
durine contrast iniection is associated with ventricular fibtil- 
lation-in approxi&tely I in 200 cardiac angiograp~ proce- 
dures (I). Ventricular fibrillation is probably produced by 
transient hwocalcemiu mediated by the binding of calcium 
ions by thi’radiopaque anion and ;he presence of calcium 
sequestering agents (15-17). Improvements in fomwlations 
of all contrast agents (ionic and nonionic) have reduced the 
incidence of ventricular fibrillation during coronary andog- 
raphy. However, available evidence indicates a greater 
reduction in the frequency of adverse electraphysiologic 
phenomena when the newer low osmolar agents are em- 
ployed. The nonixic agents produce less b=dycardia. fewer 
alterations in T wave configuration and less ventricular 
fibrillation (18.11)). However. there exist no published, coo- 
trolled trials demonstrating that the reduced incidence of 
adverse electrophysiologic effects results in improved pa- 
tient outcome or reduced hospital costs. 
Hemodynamic Effects of Contrast Media 
The hemodynamic effects of intracardiac or intracoronary 
administration of iodinated contrast agents are also well 
established (4-7,9). lntracoronary injection of conventional 
high osmolar agents produces depression in myocardial 
contractile performance. This results in a decrease in blood 
pressure and first derivative of left ventricular pressure 
(dP/dt) followed by an increase in left ventricular end- 
diastolic pressure. A rebound compensatory increase in 
blood pressure, probably mediated by baroreceptor reflexes. 
occur; within 8 io IO s &ter admini&tion ofhigh osmolar 
cootrast agents. The decrease in blood pressure or the 
occurrence of rebound hypertension, or both, may provoke 
or exacerbate myocardial ischemia, an effect that is usually 
transient but may be sustained in patients with severe 
coronary artery obstruction or unstable ischemic syndromes 
as well as in those with severe eortic valve stenosis or severe 
heart failure. The newer low osmolar contrast agents pro- 
duce little or no depression of myocardisl contractility and 
only a minimal decrease in blood presswe (7-W). Accord- 
ingly, the nonionic agents are r&xted as less likely to 
provoke myocardial &hernia. 
Administration of high osmolar contrast agents produces 
a systemic arterial vasodilation. This phenomenon results in 
characteristic Rushing or sensation of warmth experienced 
by the patient. These effects are dose dependent and are 
generally much more evideni after contrast ventricutograpby 
than after intracoronary contrast injection. The sensation is 
described as unpleasant by most patients undergoing cardiac 
catheterization; particularly when the internal r&nmary 
artery is injected. This sensation is clearly reduced by low 
osmolar agents. 
Anticoagulant Effects of Contrasf Media 
Conventional high osmolar ionic contrast agents have 
anticoagulant and antiplatelet aggregating properties that 
may contribute to the safety of coronary arteriography. The 
newer nonionic agents exert much less anticoagulant effect. 
Some workers have suggested a higher potent~l for thmm- 
bosnicitv with the nonionic contrast media (20-27). The 
low osm&r ionic agent ioxaglate is reported to have anti- 
coagulant properties similar to those of conventional ionic 
contrast media. Thrombi formed during contact between 
blood and low osmolar contrast media may be resistant to 
!hrombolysis (22). Clinically significant tbromboembolic 
phenomena have been described and may be more common 
with nonionic agents (26). These differences have resulted in 
warnings by the manufacturers of the nonionic agents to 
avoid prolonged contact between blood and contrast media. 
Whether the lesser anticoagulant effects of low osmolar 
contrast media are clinically important is an area of contro- 
versy. Proponents of low osmolar agents have argued that 
minimizing blood-contrast medium contact is prudent cath- 
eterizalion and angiographic practice regardless of the agent 
utilized. They propose that meticulous angiographic tech- 
nique can reduce or eliminate any theoretic thromboembolic 
risk and that the reduced hemodynamic and eiectrophysio- 
logic effects of nonionic agents outweigh any theoretic 
increase in thromboembolic risk. An alternative point of 
view is that prolonged cootaet between blood and contrast 
medium cannot always be avoided, particularly in circum- 
stances such as balloon angioplasty. where blood Row may 
be relatively stagnant. Some have suggested that the require- 
ment for meticulous avoidance of prolonged blood-contrast 
medium contact makes nonionic agents less forgiving in the 
clinical setting. 
There are no carefully controlled prorpective trials exam- 
ining the clinical impact of the relative anticoagulant e5ects 
of high and low osmolar agents in coronary angiography or 
angioplasty. In view of the controversy concerning the 
anticoagulant properties of nonionic or low osmolar contrast 
media, it may be prudent to consider administration of 
systemic heparin when these agents are used. 
Renal Toxicity 
Administration of iodinated eootrast medium may PTD. 
dote acute renal insufficiency. This is frequently manifested 
as an alteration in the laboratory measures of renal function, 
but less commonlv rewires treatment with dialvsis or results 
in permanent i&y.A number of risk factors have been 
identified in oredictine this complication inclodina diabetes 
mellitus. multiple myioma and ;olume depktiani28). Data 
from studies performed in experimental animals suggest that 
low osmolar agents may exhibit reduced renal toxicity (29). 
Some prospective clinical trials have not demonstrated any 
reduction in the risk of contrast-induced nephmpathy when 
the newer nonionic agents are employed during cardiac 
catheterization (30-33). However, a recent randomized 
comparison in patients with renal impaimtent (e.g., sworn 
creatinine 81.5 mpl) found that a low osmolar, nonionic 
agent was less nephrotoxic than a high osmolar, ionic agent. 
but the difference in nephrotoxicity was small (34). These 
findings were confirmed in another stody of more than I, IO0 
patients (35). In the latter trial all patients received standard 
hydration in addition to either a nonionic, low osmolar agent 
or a high osmolar agent. The relative risk of nephrotoxicity 
doubleh comparing the high osmolar to the l&v osmolar 
went. The oossiblc clinical value of these findinas remains 
uncertain. 
Allergic .Munifesfations 
A.xxphylactoid reactions occur in I% to 2% SC pd:eots 
undergoing procedures utilizing iodinated contrast me&a. 
The incidence of severe reactions is approximNy 0. I% and 
the incidence of mortality <I in ~O,IXQ cases. In one recent 
cardiac catheterization trial, urticaria was more frequen: in 
the ionic. high osmolar group than in the nonionic, low 
osmolar group (32). Another study comparing two low 
osmolar agents showed more allergic reactions in the group 
with the ionic foxnulation (ioxaglate) than in the group with 
the nonionic formulation (iopamidol) (36). Thus. mild aller- 
gic reactions may be reduced when the nonionic agents are 
used, although the effect on the incidence of anapbylactoid 
reactions is not known. 
Morbid@ and Mortality 
Fatal reactions to contrast media are very uncommon. 
Several very large scale radiologic studies (37-39) have 
compared complications (including mortality) in patients 
who receive contrast agents, usually intravenously, for 
procedures such as pyelography or computed tomography. 
However, these large studies were not randomized and the 
choice of contrast zgegent was determined by the radiologist. 
The low incidence of cont%t agent-related mortality in 
general radiography (I in 4O.wO) has precluded definitive 
conclusions from the published studies regarding the relative 
mortality risk of the available agents. 
RBC:IOII in either group in this study. These two studies 
excluded 21% and Im of patients, respectively, who were 
believed to represent w hlgb a risk for ionic agents by their 
attending physrcians and thus do not represent all patients 
presenting for catheter&ion. A study from Emory Univer- 
sity (40) randomized 913 pstients undergoing l,OS8 percuta- 
neous transluminal coronary angioplasty procedures and 
showed a reiuced incidence of serious arrhythmias in the 
group receivmg a nonionic agent but no reduction in death, 
myocardial infarction or need for surgery. 
The Johns Hopkins (31) and Canadian (32) studies esti- 
lnated net costs per case to prevent a m&erate or severe 
reaction. citing figures ofSl.698 and $2.363, respectively, for 
a strategy employing low osmalar. nonionic agents in high 
nsk cases only. WS”S about twofold to threefold higher 
costs per case if such agents were given to all patierds. In the 
nephrotoxicity study from the Mayo Clinic (34). an esti- 
mated additional cost of about 3900,wO would be required i’ 
a low osmolar contrast medium was used in the approxi- 
mately 5.OM cases studied yearly. 
The prospective studies (3X93 of contrast reactions in 
general radiographic applications have documented a reduc- 
tion in the risk of major and minor complications when low 
osmolar agents are utilized. However, most of the reactions 
experienced are minor and neither prolong hospital stay nor 
result in an adverse outcome. 
In a randomized trial of 443 patients undergoing elective 
cardiac catheterization, Hlatky et al. (33) found no signifi- 
cant increase in the incidence-of major adverse events but 
did find an increase in adverse events overall in patients 
receiving an ionic versus a nonionic agent. These investiga- 
tors estimated the overall costs of the two agents. including 
costs of treating adverse reactions. The only significant 
difference between the two grwps was the increased cost of 
the nonionic agent, which averaged $Ig6/case. Only II 
patients undergoing emergency cardiac catheterization for 
acute myocardird infarction were excluded from this study 
(33). Two additional randomized trials of nonionic and ionic 
contrast agents in patients undergoing cardiac catheteriza- 
lion (31,32) were recently reported. In a SOS-patient study 
from Johns Hopkins (31). there were no di5mences in severe 
reactions between groups receiving either an ionic or a 
nanionic contrast medium. There was a threefold increase in 
moderate reactions in the group receiving the ionic contrast 
agent. Eiibty-ii+c percent of the patients with m&rare or 
severe reactions were SO years of age or had unstable 
angina. A 1.4%patient randomized Canadian study (32) 
found an increased incidence of both mild and severe ad- 
verse reactions among patients in the group receiving the 
ionic contrast agent. Most of the reac!‘ans occurred in 
patients with severe coronary disease or unstable angina. 
There were no deaths or permanent sequelae from any 
The estimated incremental cost per patient for unirerwl 
use of low osmoiar contrast agents in cardiac catheterization 
is II00 to $200. Because there are annually approximately I
million catheterizations performed. the cost of conversion to 
nonionic agents is estimated at $IOO-SZZW million. These 
health care costs an distributed in a ntidy of ways. Many. 
but not all. third-patty insurers provide additional payments 
for the costs associated with low osmolv conhat agnt 
admiastration. 
Controversy exists regarding :he reasons for the rela- 
tively high costs of low osmolar nonionic agents. Suppliers 
of these agents cite high development and manufacturing 
costs as the primary explanation for these costs. Critics of 
the cost of low osmolar agents point out that the same low 
osmolar agents are sold for as little as 3b% of the U.S. price 
in overseas markets. 
Risk/Benefit Srraiegies 
Some authorities (41,42) recommend use of nonionic 
contrast agents for patients at high ix’ ior complications. 
F’roponents of this approach cite the potential for cost 
savings in comparison to universal e.nployment of the more 
expensive agents. Opponents .if selective use of nanianic 
agents cite the difficulty in predicting which patients will 
suffer adverse complications before undertaking the proce- 
due. 
Summury 
Low osmolar contrast agents produce less adverse elec- 
trophysiologic and hemodynamic alterations during cardiac 
catheterization. The nonionic agents probably reduce the 
risk of provoking myocardial &hernia during coronary 
atetiography or ventriculography. Patients also report less 
subjective sensation of discomfort during administration of 
l&mnmlar gents for cardiovascular p&dures. 
However, nonionic agents have not been proved to 
reduce the incidence of several serious complications of 
cardiac catheterization, including acute renal failure and 
anaphylactoid reaction. Although evidence is inconclusive, 
there may be an increased risk of thromboembolic compli- 
cations during cardiac catheterization when certain low 
ow~lar nonionic agents are administered. Nonionic con- 
trast agents have not been definitely proved to reduce the 
risk of death &ter cardiac catheterization. 
Conclusion and Recommendations 
On the basis of the available data, nonionic contrast 
agents may be of value in selected patients at high risk for 
hemodynamic complications during cardiac catheterization 
and In patients with a history of allergic reaction to contrast 
medium. These include patients with congestive heart fail- 
ure, severe amtic stenosis, cardiogenic shock and left main 
coronary artery disease. Whether low osmolar agents reduce 
the risk of catheterization in patients with unstable angina or 
evolving myocardial infarction, or during balloon angio- 
plasty remains uncertain. Several of the low osmolar ugent~ 
exert a lesser anticoagulant effect than that of conventional 
ionic agents and may increase the risk of thrombcembcdic 
complications during catheterization. 
There are no conclusive data to suppal the universal use 
of nonionic contrast agents in routine cardiac catheteriza- 
tion, in view of the increased cost. In the absence of 
definitive data, the decision to use low osmolar contrast 
agents is a matter of individual preference. The American 
College of Cardiology supports the concept of a large scale 
mwective clinical trial to evaluate the relative benefits and 
&t&ectiveness of the available radiopaque iodinated con- 
trast agents in cardiac catheterization. The ACC supports 
the principle that cardiovascular practitioners, in consulta- 
tion with their patients, should d&mine the choice of 
contrast agent for cardiovascular procedures. 
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